• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Mdxhealth Appoints Michael Holder to Board of Directors and Announces Management Change

    7/3/25 1:00:00 PM ET
    $CTKB
    $MDXH
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Medical Specialities
    Health Care
    Get the next $CTKB alert in real time by email

    IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May.

    Mr. Holder is a highly accomplished executive with over 30 years of diverse experience, including nine board, four CEO, and five CFO roles across public and private biotech, medtech, health tech, pharma, and wellness companies. His expertise encompasses corporate strategy, M&A, corporate governance, and sales productivity. He's led a $250M private investment company and most recently served as CEO of Sensable Health, an AI-powered wellness program, while also holding board positions at Cytek Biosciences Inc. (NASDAQ:CTKB, where he is Chair of the Audit Committee)), and Keyron Medical Ltd. Mr. Holder received an MBA from the Wharton School, a BS in Business from the University of North Carolina, and previously earned his Certified Public Accountant licensure.

    Michael K. McGarrity, CEO, commented: "We are incredibly excited to welcome Michael Holder to our Board of Directors as the Chair of our Audit Committee. Michael's remarkable 30-plus years of diverse experience across the biotech, medtech, and pharma industries, combined with his deep expertise in corporate strategy, fundraising, and his financial acumen, will be invaluable as we continue to generate industry-leading growth within the urology markets that we serve."

    In addition, the Company announced that Ron Kalfus has resigned from his position as Chief Financial Officer to pursue other opportunities. Mr. Kalfus will continue to serve in the role of CFO until his departure on July 30, 2025, at which time the CFO responsibilities at mdxhealth will be assumed on an interim basis by Scott McMahan, Vice President of Finance and Accounting.

    Mr. McGarrity continued, "On behalf of mdxhealth, I would like to thank Ron for his partnership and contributions during a period of significant growth for our company over the last 6 years. Ron has been a valuable member of our executive leadership team, and we wish him the very best in his future endeavors."

    Koen Hoffman, Board Chair, commented: "On behalf of the Board of Directors, I would like to welcome Michael Holder and thank Regine Slagmulder for her valued service as Chair of our Audit Committee, as well as Ron Kalfus for his service as CFO. Over the years, Regine and Ron have significantly contributed to our progress with the utmost integrity, professionalism and expertise."

    About mdxhealth

    Mdxhealth is a leading precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company's tests are based on proprietary genomic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis and prognosis of urologic cancers and other urologic diseases. The Company's U.S. headquarters and laboratory operations are in Irvine, California, with additional laboratory operations in Plano, Texas. European headquarters are in Herstal, Belgium. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.

    This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as "potential," "expect," "will," "goal," "next," "potential," "aim," "explore," "forward," "future," and "believes" as well as similar expressions. Forward-looking statements contained in this release include, but are not limited to, statements regarding expected future operating results; and our strategies, positioning, resources, capabilities and expectations for future events or performance. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results, product development efforts, our strategies, positioning, resources, capabilities and expectations for future events or performance. Important factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements include, among others, the following: uncertainties associated with global macroeconomic conditions; our ability to successfully and profitably market our products; the acceptance and reimbursement of our products and services by healthcare providers and payers; our ability to obtain and maintain regulatory approvals and comply with applicable regulations; the possibility that the anticipated benefits from our business acquisitions like our acquisition of the Oncotype DX® GPS prostate cancer business will not be realized in full or at all or may take longer to realize than expected; and the amount and nature of competition for our products and services. Other important risks and uncertainties are described in the Risk Factors sections of our most recent Annual Report on Form 20-F and in our other reports filed with the Securities and Exchange Commission. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws..

    NOTE: The mdxhealth logo, mdxhealth, Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate Score, GPS and Monitor mdx are trademarks or registered trademarks of MDxHealth SA. The GPS test was formerly known as and is frequently referenced in guidelines, coverage policies, reimbursement decisions, manuscripts and other literature as Oncotype DX Prostate, Oncotype DX GPS, Oncotype DX Genomic Prostate Score, and Oncotype Dx Prostate Cancer Assay, among others. The Oncotype DX trademark, and all other trademarks and service marks, are the property of their respective owners.

    For more information:

    [email protected]

    LifeSci Advisors (IR & PR)

    John Fraunces

    Managing Director

    Tel: +1 917 355 2395

    [email protected] 

    [email protected]

    Attachment

    • MDXH PR Final


    Primary Logo

    Get the next $CTKB alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CTKB
    $MDXH

    CompanyDatePrice TargetRatingAnalyst
    Cytek Biosciences Inc.
    $CTKB
    5/9/2025$4.00Buy → Hold
    TD Cowen
    Cytek Biosciences Inc.
    $CTKB
    1/31/2025$7.00 → $4.50Buy → Sell
    Goldman
    MDxHealth SA
    $MDXH
    10/31/2024$7.00Buy
    Lake Street
    Cytek Biosciences Inc.
    $CTKB
    12/14/2023$9.00Overweight
    Stephens
    Cytek Biosciences Inc.
    $CTKB
    7/19/2023Mkt Perform
    Raymond James
    MDxHealth SA
    $MDXH
    5/31/2023$7.00Outperform
    TD Cowen
    MDxHealth SA
    $MDXH
    7/18/2022$18.00Outperform
    Oppenheimer
    Cytek Biosciences Inc.
    $CTKB
    2/15/2022$27.00 → $18.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $CTKB
    $MDXH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Chin Richard

      4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

      6/20/25 4:31:59 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 3 filed by new insider Chin Richard

      3 - Cytek Biosciences, Inc. (0001831915) (Issuer)

      6/20/25 4:27:18 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 4 filed by Director Neff Deborah J

      4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

      6/20/25 4:25:14 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $CTKB
    $MDXH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Mccombe William D. bought $97,300 worth of shares (35,000 units at $2.78), increasing direct ownership by 169% to 55,746 units (SEC Form 4)

      4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

      6/3/25 5:39:17 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $CTKB
    $MDXH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cytek Biosciences downgraded by TD Cowen with a new price target

      TD Cowen downgraded Cytek Biosciences from Buy to Hold and set a new price target of $4.00

      5/9/25 8:41:00 AM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek Biosciences downgraded by Goldman with a new price target

      Goldman downgraded Cytek Biosciences from Buy to Sell and set a new price target of $4.50 from $7.00 previously

      1/31/25 6:59:30 AM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Lake Street initiated coverage on MDxHealth SA with a new price target

      Lake Street initiated coverage of MDxHealth SA with a rating of Buy and set a new price target of $7.00

      10/31/24 8:59:17 AM ET
      $MDXH
      Medical Specialities
      Health Care

    $CTKB
    $MDXH
    SEC Filings

    See more
    • SEC Form 6-K filed by MDxHealth SA

      6-K - MDxHealth SA (0001872529) (Filer)

      7/3/25 4:48:27 PM ET
      $MDXH
      Medical Specialities
      Health Care
    • SEC Form 8-K filed by Cytek Biosciences Inc.

      8-K - Cytek Biosciences, Inc. (0001831915) (Filer)

      6/24/25 4:05:58 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 6-K filed by MDxHealth SA

      6-K - MDxHealth SA (0001872529) (Filer)

      6/6/25 5:12:22 PM ET
      $MDXH
      Medical Specialities
      Health Care

    $CTKB
    $MDXH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mdxhealth Appoints Michael Holder to Board of Directors and Announces Management Change

      IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May. Mr. Holder is a highly accomplished executive with over 30 years of diverse experience, including nine board, four CEO, and five CFO roles across public and private biotech, medtech, health tech, pharma, and wellness companies. His expertise encompasses corporate strategy, M&A, corporate governance, and sales productivity. He's led a $25

      7/3/25 1:00:00 PM ET
      $CTKB
      $MDXH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Medical Specialities
      Health Care
    • Cytek® Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora™ Evo Flow Cytometer

      FREMONT, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- In a move that underscores its dedication to shaping the future of cell analysis, Cytek Biosciences, Inc. (NASDAQ:CTKB) today announced the launch of the Cytek Aurora™ Evo system, a new full spectrum flow cytometer that improves on its flagship Cytek Aurora system. First launched in 2017 to address the limitations of existing flow cytometry technologies, Cytek's Full Spectrum Profiling™ (FSP®) systems have become the spectral technology of choice for researchers worldwide, with over 2,600 peer-reviewed publications citing its use – more than any other spectral flow cytometer. Building on this groundbreaking success, the new Cytek Aurora E

      5/29/25 5:00:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek Biosciences to participate at the Goldman Sachs 46th Annual Global Healthcare Conference

      FREMONT, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming Goldman Sachs 46th Annual Global Healthcare Conference in Miami Beach, FL. Cytek management is scheduled to participate in a fireside chat on Wednesday, June 11th at 11:40 a.m. Pacific Time / 2:40 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at: investors.cytekbio.com. About Cytek Biosciences, Inc. Cytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing the next

      5/28/25 4:05:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $CTKB
    $MDXH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Cytek Biosciences Inc.

      SC 13G - Cytek Biosciences, Inc. (0001831915) (Subject)

      11/14/24 4:35:51 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by MDxHealth SA

      SC 13G - MDxHealth SA (0001872529) (Subject)

      11/14/24 3:15:43 PM ET
      $MDXH
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cytek Biosciences Inc.

      SC 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)

      11/14/24 1:42:15 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $CTKB
    $MDXH
    Financials

    Live finance-specific insights

    See more
    • MDxHealth Reports Q1-2025 Results

      Year-over-year Q1 revenues increase by 22% to $24.3 million71% year-over-year improvement in adjusted EBITDA in first quarterConference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – May 14, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the first quarter ended March 31, 2025. Michael K. McGarrity, CEO of mdxhealth, commented: "mdxhealth delivered a strong first quarter, marked by our 16th consecutive quarter of 20% or greater revenue growth, fueled by continued execution by our team and strong demand for our precision diagnostics. Our expa

      5/14/25 4:00:00 PM ET
      $MDXH
      Medical Specialities
      Health Care
    • Cytek Biosciences Reports First Quarter 2025 Financial Results

      FREMONT, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2025. First Quarter Highlights Total revenue for the first quarter of 2025 was $41.5 million, representing a 7.6% decrease compared to the first quarter of 2024Expanded to a total installed base of 3,149 Cytek instruments, including the Amnis® and Guava® instruments shipped since the acquisition of the product lines in February 2023, adding 115 units in the first quarter of 2025Commenced operations in Singapore to access low-cost manufacturing, increa

      5/8/25 4:05:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Mdxhealth to Release First Quarter 2025 Financial Results on May 14

      Company to Host Conference Call with Live Q&A, May 14, 2025, at 4:30pm ET / 22:30 CET IRVINE, California – April 30, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH), a leading precision diagnostics company, today announced it will release its financial results for the first quarter ended March 31, 2025, after market close on Wednesday, May 14, 2025. Title:Mdxhealth Presents First Quarter 2025 Financial Results andCorporate Update Conference Call and WebcastSpeakers:Michael K. McGarrity, Chief Executive OfficerRon Kalfus, Chief Financial OfficerDate:May 14, 2025Time:4:30pm ET/ 22:30 CETConference Call Dial-in Details:United States: 1-844-825-9789Belgium: 0800 38 961The Netherlands: 0800

      4/30/25 4:00:00 PM ET
      $MDXH
      Medical Specialities
      Health Care

    $CTKB
    $MDXH
    Leadership Updates

    Live Leadership Updates

    See more
    • Mdxhealth Appoints Michael Holder to Board of Directors and Announces Management Change

      IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May. Mr. Holder is a highly accomplished executive with over 30 years of diverse experience, including nine board, four CEO, and five CFO roles across public and private biotech, medtech, health tech, pharma, and wellness companies. His expertise encompasses corporate strategy, M&A, corporate governance, and sales productivity. He's led a $25

      7/3/25 1:00:00 PM ET
      $CTKB
      $MDXH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Medical Specialities
      Health Care
    • Cytek Announces Resignation of Chief Operating Officer Chris Williams

      FREMONT, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced that its Chief Operating Officer, Chris Williams, will resign his position effective September 27, 2024, to accept a CEO position at another company. Cytek has chosen not to replace the COO position, opting instead to restructure the organization to create a flatter, more efficient management structure. During his tenure, Williams played key roles in the company's growth, spearheading initiatives that improved operational processes and paving the way for Cytek's future success. His leadership has been integral to enhancing the company's ef

      9/12/24 3:20:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Mdxhealth Appoints Sanford J. Siegel, M.D. to Board of Directors

                  Mdxhealth Appoints Sanford J. Siegel, M.D. to Board of Directors IRVINE, CA, and HERSTAL, BELGIUM – July 8, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced the appointment of Sanford J. Siegel, M.D. to its Board of Directors. Dr. Siegel will be taking the seat of Lieve Verplancke M.D., who is stepping down from the Board of mdxhealth. Dr. Siegel has more the 45 years of experience as a practicing urologist and over 35 years of executive leadership experience. Dr. Siegel currently serves as the Chairman of the Board of United Urology Group, having previously served as its Chie

      7/8/24 8:00:00 AM ET
      $MDXH
      Medical Specialities
      Health Care